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Proteomic analysis of rhein-induced cyt: ER stress
mediates cell death in breast cancer cells†
Hui-Ju Huang,‡a Chi-Chen Lin,‡bcde Hsiu-Chuan Chou,f Yi-Wen Chen,a
Szu-Ting Lin,a Yi-Chieh Lin,a Dai-Ying Lin,a Kevin W. Lyugh and Hong-Lin Chan*a
Rhein is a natural product purified from herbal plants such as Rheum palmatum, which has been shown
to have anti-angiogenesis and anti-tumor metastasis properties. However, the biological eﬀects of rhein
on the behavior of breast cancers are not completely elucidated. To evaluate whether rhein might be
useful in the treatment of breast cancer and its cytotoxic mechanism, we analyzed the impact of rhein
treatment on diﬀerential protein expression as well as redox regulation in a non-invasive breast cancer
cell line, MCF-7, and an invasive breast cancer cell line, MDA-MB-231, using lysine- and cysteine-
labeling two-dimensional diﬀerence gel electrophoresis (2D-DIGE) combined with MALDI-TOF/TOF
mass spectrometry. This proteomic study revealed that 73 proteins were significantly changed in protein
expression; while 9 proteins were significantly altered in thiol reactivity in both MCF-7 and MDA-MB-231
cells. The results also demonstrated that rhein-induced cytotoxicity in breast cancer cells mostly
involves dysregulation of cytoskeleton regulation, protein folding, the glycolysis pathway and
transcription control. A further study also indicated that rhein promotes misfolding of cellular proteins as
well as unbalancing of the cellular redox status leading to ER-stress. Our work shows that the current
proteomic strategy oﬀers a high-through-put platform to study the molecular mechanisms of rhein-
induced cytotoxicity in breast cancer cells. The identified diﬀerentially expressed proteins might be
further evaluated as potential targets in breast cancer therapy.
1. Introduction
Rhein is a natural product purified from herbal plants such as
Rheum palmatum.1 It has long been used to reduce metabolic
disorders,2 obesity,3 angiogenic eﬀects4 and exhibits anti-
bacterial activity.5 Rhein has also been reported to show anti-
tumor metastasis in human tongue cancer via the inhibition of
gene expression of matrix metalloproteinase-9.6 It has also
been demonstrated that rhein inhibits invasion of human
nasopharyngeal carcinoma cells by down-regulation of the
vascular endothelial growth factor.7 Recently, the generation
of reactive oxygen species (ROS) has been reported to be an
important factor in rhein-induced apoptosis of cancer cells.8
However, the detailed mechanisms of rhein-induced cytotoxi-
city remain poorly understood.
Proteomics is a powerful strategy to examine protein expres-
sion alterations in response to various treatments or physiological
conditions. 2-DE has long been recognized as an important
technique in the proteomic field for large-scale protein profiling
within biological samples as well as plays a complementary role to
LC-MS-based proteomic analysis.9 Nevertheless, reliable quantita-
tive comparison across gels remains the main challenge in 2-DE
analysis. A significant progress in 2-DE-based protein quantifica-
tion and detection was accomplished by the introduction of
2D-DIGE, where numerous protein samples can be co-detected
on the same 2-DE gel using diﬀerential fluorescent labeling (Cy2,
Cy3 and Cy5). This advancement improves gel-to-gel variation and
allows comparison of the relative amount of resolved proteins
across diﬀerent gels by using a fluorescently-labeled internal
standard. In addition, the 2D-DIGE proteomic analysis has the
benefits of a broader linear dynamic range of detection, greater
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reproducibility and higher sensitivity than traditional 2-DE.9 This
innovative proteomic analysis relies on the pre-labeling of protein
samples on the amino group of lysine residues with fluorescent
dyes (Cy2, Cy3 and Cy5) before electrophoresis. Each of the three
dyes has a distinct fluorescent wavelength, allowing comparison
of experimental protein samples and an internal standard to be
concurrently separated in the same gel. The internal standard,
which is a pool of an equal amount of all protein samples, helps
to provide precise spot matching and normalization as well as
increases statistical confidence in relative quantification across
diﬀerent gels.10–14 Recently, a cysteine labeling version of
2D-DIGE was developed, by using ICy dyes (iodoacetyl cyanine
dyes) which react with the free thiol group of cysteines through
alkylation. A pair of ICy dyes (ICy3 and ICy5) have been used to
examine redox-dependent protein thiol modifications in a
model cell system exposed to hydrogen peroxide and in plasma
fractions exposed to UVC15 as well as used in the analysis of
redox-regulation of cancer cells.16
The main purpose of the current study was to use a proteomic
analysis combining lysine and cysteine 2D-DIGE and mass spec-
trometry to investigate the inhibitory eﬀects of rhein on breast
cancer cells (MCF-7 and MDA-MB-231). MCF-7 and MDA-MB-231
cells, originally derived from pleural eﬀusion of patients with low-
and high-invasive breast ductal carcinoma, were used as model
breast cancer systems to clarify the molecular eﬀects of rhein
including themonitoring of rhein-induced protein expression and
redox modification of intracellular proteins.
2. Materials and methods
2.1 Chemicals and reagents
Generic chemicals including rhein were purchased from Sigma-
Aldrich (St. Louis, USA), while reagents for 2D-DIGE were
purchased from GE Healthcare (Uppsala, Sweden). The synthesis
of the ICy3 and ICy5 dyes has been previously reported by our
group.15 All primary antibodies were purchased from Genetex
(Hsinchu, Taiwan) and anti-mouse, and anti-rabbit secondary
antibodies were purchased fromGEHealthcare (Uppsala, Sweden).
All the chemicals and biochemicals used in this study were of
analytical grade.
2.2 Cell lines and cell cultures
The breast epithelial cell line MCF-10A was a gift from Dr
Wun-Shaing Wayne Chang, National Health Research Institute,
Taiwan. The breast cancer cell lines MCF-7 and MDA-MB-231
were purchased from American Type Culture Collection
(ATCC), Manassas, VA. MCF-10A was maintained in Dulbecco’s
Modified Eagle’s medium and F-12 medium (DMEM/F-12)
supplemented with 5% horse serum, L-glutamine (2 mM),
streptomycin (100 mg mL1), penicillin (100 IU mL1), the
epidermal growth factor (20 ng mL1) (all from Gibco-
Invitrogen Corp., UK), insulin (10 mg mL1) (Sigma) and hydro-
cortisone (0.5 mg mL1) (Sigma). MCF-7 and MDA-MB-231 were
maintained in Dulbecco’s Modified Eagle’s medium (DMEM)
supplemented with 10% (v/v) fetal calf serum (FCS), L-glutamine
(2 mM), streptomycin (100 mg mL1), and penicillin (100 IUmL1)
(all from Gibco-Invitrogen Corp., UK). All cells were incubated at
37 1C and 5% CO2.
2.3 MTT cell viability assay
The detailed MTT procedure has been described in our previous
publication.16 MCF-10A cells, MCF-7 cells and MDA-MB-231 cells
(5000 cells per well) growing exponentially were seeded into
96-well plates. The culture cells were incubated for 24 h before
treatment with indicative concentrations (a dose range
0–100 mg mL1) of rhein for 24 h and untreated as control.
After removal of the medium, 100 mL of MTT working
solution (1 mg mL1) (Sigma) was added into each well,
followed by further incubation at 37 1C in 5% CO2 for 4 h.
The supernatant was carefully removed followed by addition
of 100 mL of DMSO to each well and shaken for 15 min. The
absorbance of samples was measured at a wavelength of
540 nm in a multi-well plate reader. Values were normalized
against the untreated samples and were averaged from 8
independent measurements.
2.4 Immunofluorescence
The detailed immunofluorescence procedure has been described
in our previous publication.17 For immunofluorescence staining,
cells were fixed with 4% paraformaldehyde for 25 min and the
attached cells washed twice with PBS, and then permeabilized
with 0.1% Triton X-100 for 10 min, blocked with 5% bovine serum
albumin in PBS for 1 h, followed by incubation with primary
antibodies at 4 1C for 24 h. After three PBS washes, samples were
incubated with appropriate fluorescently labeled secondary anti-
bodies diluted (1 : 100) in 2.5% BSA/PBS. Coverslips were then
washed three times with PBS and at least twice with ddH2O before
being mounted with 4 mL antifade mounting reagent (Invitrogen)
and dried in the dark at 4 1C. For image analysis, cells were
imaged using a Zeiss Axiovert 200 M fluorescence microscope
(Carl Zeiss, Germany). All laser intensities used to detect the same
immunostained markers were the same and all laser intensities
used for capturing images were not saturated. Images were
exported as .tif files using Zeiss Axioversion 4.8 and processed
using Adobe Photoshop version 7.0 software.
2.5 Enzyme-linked immunosorbent assay (ELISA) analysis of
plasma
The detailed ELISA procedure has been described in our
previous publication.18 EIA polystyrene microtiter plates were
coated with 50 mg of the protein lysate sample and incubated at
37 1C for 2 h. The plate was washed three times with phosphate
buﬀered saline with Tween-20 (PBS-T) and three times with
PBS. Plates were then blocked with 100 mL of 5% skimmed milk
in PBS at 37 1C for 2 h and then washed three times with PBST.
Antibody solution was added and incubated at 37 1C for 2 h.
After washing with PBST and PBS 10 times in total, 100 mL of
peroxidise-conjugated secondary antibody in PBS was added for
incubation at 37 1C for 2 h. Following 10 washes, 100 mL of
3,30,5,50-tetramethyl benzidine (Pierce) was added. After incu-
bation at room temperature for 30 min, 100 mL of 1 M H2SO4
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was added to stop the reaction and the absorbance at 450 nm
measured using a Stat Fax 2100microtiter plate reader (Awareness
Technology Inc. FL, USA).
2.6 Sample preparation for 2D-DIGE experiment, gel image
analysis, protein staining, in-gel digestion and MALDI-TOF MS
analysis
MCF-7 and MDA-MB-231 cells treated with individual IC50
concentrations of rhein in complete cell culture medium for
24 h or treated with vehicle (DMSO, 0.1% (w/v) in media), were
washed twice in 0.5 PBS, drained well and lysed in 2-D lysis
buﬀer containing 4% w/v CHAPS, 7 M urea, 2 M thiourea,
10 mM Tris-HCl pH 8.3 and 1 mM EDTA. The detailed experi-
mental procedures have been described in our previous
study.16,17,19 Notably, peaks in the mass range of m/z 800–3000
were used to generate a peptide mass fingerprint that was
searched against the Swiss-Prot/TrEMBL database (v57.12) with
513877 entries using Mascot software v2.2.06 (Matrix Science,
London, UK). The following parameters were used for the search:
Homo sapiens; tryptic digest with a maximum of 1 missed
cleavage; carbamidomethylation of cysteine, partial protein
N-terminal acetylation, partial methionine oxidation and partial
modification of glutamine to pyroglutamate and amass tolerance
of 50 ppm. Identification was accepted based on significant
MASCOT Mowse scores (p o 0.05), spectrum annotation and
observed versus expected molecular weight, and pI on 2-DE as
well as at least 5 peptides in each identified protein.
For redox DIGE analysis, cells were lysed in 2-DE buﬀer
(4% w/v CHAPS, 8 M urea, 10 mM Tris-HCl pH 8.3 and 1 mM
EDTA) in the presence of ICy3 or ICy5 (80 pmol per mg protein)
on ice to limit post-lysis thiol modification. Test samples were
labeled with the ICy5 dye and mixed with an equal amount of a
standard pool of both samples labeled with ICy3. Since ICy dyes
interfered with the protein assay, protein concentrations were
determined on replica lysates not containing dye. Lysates were
left in the dark for 1 h followed by labeling with Cy2 to monitor
the protein level The reactions were quenched with DTT
(65 mM final concentration) for 10 min followed by L-lysine
(a 20-fold molar ratio excess of free L-lysine to Cy2 dye) for a
further 10 min. Volumes were adjusted to 450 mL with buﬀer
plus DTT and IPG buﬀer for rehydration. All samples were run
in triplicate against the standard pool.
2.7 Immunoblotting analysis
Immunoblotting analysis was used to validate the diﬀerential
abundance of mass spectrometry identified proteins as well as
determine the protein expression in cells. The detailed experi-
mental procedures were described in our previous reports.10,20,21
Briefly, cells were lysed with a lysis buﬀer containing 50 mM
HEPES pH 7.4, 150 mM NaCl, 1% NP40, 1 mM EDTA, 2 mM
sodium orthovanadate, 100 mgmL1 AEBSF, 17 mgmL1 aprotinin,
1 mg mL1 leupeptin, 1 mg mL1 pepstatin, 5 mM fenvalerate, 5 mM
BpVphen and 1 mM okadaic acid prior to protein quantification
with Coomassie Protein Assay Reagent (BioRad). 30 mg of protein
samples were diluted in Laemmli sample buﬀer (final concentra-
tions: 50 mM Tris pH 6.8, 10% (v/v) glycerol, 2% SDS (w/v), 0.01%
(w/v) bromophenol blue) and separated by 1D-SDS-PAGE following
standard procedures. After transferring separated proteins onto
0.45 mm Immobilon P membranes (Millipore), the membranes
were blocked with 5% w/v skim milk in TBST (50 mM Tris pH 8.0,
150 mM NaCl and 0.1% Tween-20 (v/v)) for 1 h. Membranes were
incubated in primary antibody solution in TBS-T containing 0.02%
(w/v) sodium azide for 2 h. Membranes were washed in TBS-T
(3  10 min) and then probed with the appropriate horseradish
peroxidase-coupled secondary antibody (GE Healthcare). After
washing in TBS-T 6 times (15 min each), immunoprobed proteins
were visualized using an enhanced chemiluminescence method
(Visual Protein Co.).
2.8 Assay for endogenous reactive oxygen species using
DCFH-DA
MCF-7 and MDA-MB-231 cells (10 000 cells per well) were
incubated with the indicated concentrations of rhein for
20 min. After two washes with PBS, cells were treated with
10 mM of 2,7-dichlorofluorescin diacetate (DCFH-DA; Molecular
Probes) at 37 1C for 20 min, and subsequently washed with PBS.
Fluorescence was recorded at an excitation wavelength of
485 nm and an emission wavelength of 530 nm.
2.9 Assay for the eﬀect of N-acetylcysteine on rhein-induced
cell death
To examine the eﬀect of an antioxidant, N-acetylcysteine (NAC),
on rhein-induced cell death, cells were pretreated with NAC
(10 and 20 mM) or vehicle (PBS) for 3 h before the treatment
with indicated concentrations of rhein for 24 h or left
untreated. After removal of the medium, 50 mL of MTT working
solution (1 mg mL1) (Sigma) was added to the cells in each
well, followed by a further incubation at 37 1C for 4 h. The
supernatant was carefully removed. 100 mL of DMSO was added
to each well and the plates shaken for 20 min. The absorbance
of samples was then measured at 540 nm in a multi-well plate
reader. Values were normalized against the untreated samples
and were averaged from 4 independent measurements.
2.10 Validation of thiol reactivity changes by
immunoprecipitation coupled to immunoblotting
Rhein treated MCF-7 and MDA-MB-231 cells were lysed in the
presence of ICy3 or ICy5 dyes to limit post-lysis thiol modifica-
tion. The labeling reactions were performed in the dark at 37 1C
for 1 h and then quenched with a 2-fold molar excess of DTT for
10 min. 500 mg of ICy dye-labeled cell lysate was then diluted
20-fold with NP40 buﬀer containing protease inhibitors and
then incubated with 5 mg primary antibody and 40 mL of a 50%
slurry of protein A-Sepharose for 16 h at 4 1C. Immune complexes
were then washed three times in lysis buﬀer and boiled in
Laemmli sample buﬀer prior to resolving by SDS-PAGE. ICy
images were scanned directly between low-fluorescence glass
plates using an Ettan DIGE Imager (GE Healthcare) followed by
immunoblotting analysis with the same primary antibody to
detect the specific protein. The immunoblotting procedure is
described above.
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Fig. 1 Rhein-induced loss of cell viability, increased cell apoptosis and blocked cell cycle progression in MCF-10A cells, MCF-7 cells and MDA-MB-231
cells. (A) MTT-based viability assays were performed on MCF-10A cell, MCF-7 cell and MDA-MB-231 cell cultures. Values from rhein-treatments were
normalized against individual untreated control groups and were the average of 6 independent measurements +/ the standard deviation. (B) 106 MCF-10A
cells, MCF-7 cells and MDA-MB-231 cells treated with/without 15 mg mL1 rhein were incubated with Alexa Fluor 488 and propidium iodide in 1 binding
buﬀer at room temperature for 15 min, and then stained cells were analyzed by flow cytometry to examine the eﬀect of rhein-treatment on apoptosis
in MCF-10A cells, MCF-7 cells and MDA-MB-231 cells. Annexin V is presented on the x-axis as FL1-H, and propidium iodide is presented on the y-axis as
FL2-H. LR quadrant indicates the percentage of early apoptotic cells (Annexin V positive cells), and UR quadrant indicates the percentage of late apoptotic
cells (Annexin V positive and propidium iodide positive cells). (C) Cell-cycle analysis using propidium iodide staining. The y-axis shows the intensity of PI, and
the x-axis shows the number of cells. The black lines display the full length DNA of control MCF-10A cells, MCF-7 cells and MDA-MB-231 cells; in contrast,
the red lines display the full length DNA of rhein-treated MCF-10A cells, MCF-7 cells and MDA-MB-231 cells (upper panels). The G0/G1 phase, S phase and
G2/M phase distributions of vehicle-treated and rhein-treated MCF-10A cells, MCF-7 cells and MDA-MB-231 cells (bottom panels).
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2.11 Flow cytometry analysis for apoptosis detection
Annexin-V/propidium iodide (PI) double assay was performed
using the Annexin V, Alexa Fluors 488 Conjugate Detection
kit (Life technologies). Following rhein treatment, cells were
trypsinized from culture dish and washed twice with cold PBS.
1  106 cells were resuspended in 500 mL binding buﬀer and
stained with 5 mL Alexa Fluor 488 conjugated annexin V
according to the manufacturer’s instructions. 1 mL 100 mg mL1
propidium iodide (PI) was added and mixed gently to incubate
with cells for 15 min at room temperature in the dark. After the
incubation period, samples were subjected to FCM analysis in 1 h
using BD Accuri C6 Flow Cytometry (BD Biosciences, San Jose,
CA). The data were analyzed using Accuri CFlow@ and CFlow Plus
analysis software (BD Biosciences).
3. Results
3.1 Rhein induces cell death and cell apoptosis in MCF-10A
cells, MCF-7 cells and MDA-MB-231 cells
Our previous study demonstrated that rhein is able to inhibit
cell proliferation in both HER2 overexpression and HER2-basal
expression in breast cancer cells.22 In the current study, rhein
has been shown to be less toxic to non-tumorigenic MCF-10A
breast cells in comparison to non-invasive breast cancer cells,
MCF-7, and invasive breast cancer cells, MDA-MB-231 (Fig. 1).
To evaluate the eﬀect of rhein on breast cancer cells, we
exposed MCF-10A cells, MCF-7 cells and MDA-MB-231 cells to
a dose range (0–100 mg mL1) of rhein for 24 h and performed
MTT assays. Exposure of MCF-7 cells and MDA-MB-231 cells to
rhein were shown to result in a dose-dependent loss of cell
viability. At a rhein concentration of 15 mg mL1, a significant
loss of cell viability (50%) was detectable after 24 h. In contrast,
non-tumorigenic MCF-10A breast cells were shown to have a
higher IC50 value at 35 mg mL
1 demonstrating that rhein is less
toxic for non-tumorigenic breast cells rather than for breast
cancer cells (Fig. 1A). In order to verify rhein-induced breast
cancer cell toxicity, we also examined the changes of cell
apoptosis in MCF-10A cells, MCF-7 cells and MDA-MB-231 cells
treated with 15 mg mL1 of rhein for 24 h. We used flow
cytometry with propidium iodide staining and annexin
V-conjugated Alexa Fluor 488 to analyze the percentages of
apoptotic MCF-10A cells, MCF-7 cells and MDA-MB-231 cells
treated with/without 15 mg mL1 of rhein. The experimental
data indicated that treatment of rhein increases the percen-
tages of total apoptotic cells in MCF-10A cells, MCF-7 cells and
MDA-MB-231 cells by 5.0%, 11% and 26.3%, respectively.
Notably, most of these apoptotic events were taking place in
the late apoptotic stage where the apoptotic rates were
increased for 4.8%, 14.7% and 24.4% in MCF-10A cells,
MCF-7 cells and MDA-MB-231 cells, respectively. These results
imply that rhein induces more significant cell apoptosis in non-
invasive breast cancer cells, MCF-7, as well as in invasive breast
cancer cells, MDA-MB-231, rather than in non-tumorigenic
MCF-10A breast cells and most of these apoptosis events are
involving late apoptotic stage (Fig. 1B). Further analysis of cell
Fig. 2 Eﬀect of rhein on MCF-7 and MDA-MB-231 ROS production. (A) DCFH-based intracellular ROS production assays were performed where 10000
MCF-7 and MDA-MB-231 cells were plated onto 96-well plates in medium containing 10% FBS. After 24 h, the cells were treated with the indicated
concentrations of rhein for a further 24 h. Cells were then treated with 10 mM of DCFH-DA at 37 1C for 20 min and the fluorescence images were
recorded at excitation and emission wavelengths of 485 nm and 530 nm, respectively. Each set of three fields was taken using the same exposure, and
images are representative of three diﬀerent fields. (B) Eﬀect of pretreatment of NAC (10 mM and 20 mM) or vehicle (PBS) on rhein-induced cell death in
MCF-10A, MCF-7 and MDA-MB-231 cells. Cells were treated with varying concentrations of rhein (0, 1  IC50 and 2  IC50) for 24 h and then harvested
for analysis of cell viability using the MTT assay as detailed in Materials and methods.
Molecular BioSystems Paper
Pu
bl
ish
ed
 o
n 
22
 S
ep
te
m
be
r 2
01
4.
 D
ow
nl
oa
de
d 
by
 N
at
io
na
l C
hu
ng
 H
sin
g 
U
ni
ve
rs
ity
 o
n 
12
/0
2/
20
15
 1
0:
16
:4
6.
 
View Article Online
This journal is©The Royal Society of Chemistry 2014 Mol. BioSyst., 2014, 10, 3086--3100 | 3091
cycle distributions by flow cytometry revealed that rhein can
significantly induce G2/M cell-cycle arrest in both MCF-7 cells
and MDA-MB-231 cells rather than in MCF-10A cells (Fig. 1C).
3.2 Rhein induces generation of intracellular ROS in MCF-7
cells and MDA-MB-231 cells
Previous reports have shown that rhein is able to induce
apoptosis in human prostate and colon cancer cells through
the generation of ROS.23 However, few studies of this in breast
cancer cells have been reported. Accordingly, we tested the
hypothesis whether rhein-induced cell death in breast cancer
is initiated through ROS generation. Using DCF fluorescence
as readout, treatment of MCF-7 and MDA-MB-231 cells with
1  IC50 or 2  IC50 concentrations of rhein for 20 min resulted
in a dose-dependent increase in ROS generation compared with
untreated MCF-7 and MDA-MB-231 cells (Fig. 2A). We further
Fig. 3 2D-DIGE analysis of rhein-induced diﬀerential protein expression in MCF-7 cells and MDA-MB-231 cells. (A) MCF-7 cells and MDA-MB-231 cells
were treated with an IC50 concentration of rhein for 24 h or left untreated. Lysates were prepared in triplicate and 2D-DIGE analysis performed according
to Materials and methods. 2D-DIGE images of the protein samples from untreated and rhein-treated MCF-7 cells and MDA-MB-231 cells are displayed,
respectively. (B) Identified diﬀerentially expressed protein features are annotated with spot numbers.
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checked whether a cell-permeable anti-oxidant could rescue
cells from rhein-induced cell death due to the generation of
ROS. The result demonstrated that pretreatment with NAC
oﬀered significant protection against rhein-induced cell death
in both MCF-7 and MDA-MB-231 cells at each dose of rhein. On
the other hand, the pretreatment of NAC had no significant
eﬀect on MCF-10A cells (Fig. 2B).
3.3 2D-DIGE and MALDI-TOF MS analysis of rhein-induced
proteomic alterations in MCF-7 cells and MDA-MB-231 cells
In order to analyze rhein-induced proteomic alterations, MCF-7
cells and MDA-MB-231 cells were grown on cell culture dishes
prior to treatment with an IC50 concentration (15 mg mL
1)
of rhein or treated with a vehicle. Three biological replicates
for each treatment were compared by 2D-DIGE to provide a
global overview of rhein-induced diﬀerential protein expres-
sion. Image analysis revealed more than 2094 well-defined
protein features (Fig. 3A). Those appearing in all replicates
and showing a change in average abundance of 41.5-fold
(P o 0.05) between the treated and untreated cell lysates were
excised from gels for protein identification. MALDI-TOF MS
as well as MALDI-TOF/TOF MS identification revealed 34 and
60 diﬀerentially expressed proteins between rhein-treated and
untreated MCF-7 cells and MDA-MB-231 cells, respectively
(Fig. 3B, Fig. S1 and Table S1, ESI†). More than half of the
diﬀerentially expressed proteins identified were cytosolic proteins
Fig. 4 Distribution of diﬀerentially expressed proteins from rhein-treated and untreated MCF-7 cells and MDA-MB-231 cells according to (A) the
subcellular location and (B) biological function.
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(Fig. 4A) and predominantly involved in cytoskeleton regulation,
protein folding, cytoskeleton, glycolysis, signal transduction and
transcription control (Fig. 4B).
Using functional information from the Swiss-Prot and KEGG
pathway databases, numerous biological functions were
ascribed to the identified proteins with possible roles in
rhein-induced cytotoxicity. Fig. 5 compares the expression
profiles of the diﬀerentially expressed proteins. Proteins known
to regulate protein folding, cytoskeleton regulation and glycolysis
were found to be down-regulated in both rhein-treated MCF-7
cells and MDA-MB-231 cells.
3.4 Validation of proteomic results by immunoblotting,
immunofluorescence and ELISA
To validate diﬀerential expression of the identified proteins,
immunoblotting, immunofluorescence and ELISA were performed
to compare the protein expression levels between rhein- and
vehicle control-treated MCF-7 and MDA-MB-231 cells. In general,
there was a good correlation between changes observed in the
2D-DIGE analysis and by immunoblotting/immunofluorescence/
ELISA analysis. Validation confirmed the expression levels of
cathepsin D, galectin-3, HSP-27, tropomyosin alpha-4 and destrin
by either immunoblotting or ELISA in MCF-7 cells since these
proteins play essential roles in the regulation of cell physiology
(Fig. 6). In addition, validation also confirmed the levels of 78 kDa
glucose-regulated protein, annexin A3, SCaMC-3, cofilin-1,
galectin-1, cytoskeletal 18, nucleobindin-1, peptidyl-prolyl cis–trans
isomerase A, peroxiredoxin-1, protein disulfide-isomerase A3,
stress-induced-phosphoprotein 1, tropomyosin alpha-1, cytoskeletal
19 and 60 kDa heat shock protein in MDA-MB-231 cells by
immunoblotting, immunofluorescence or ELISA (Fig. 7).
3.5 Relationship between rhein and ER-stress
ROS have emerged as major regulators of ER function as well as
unfolded protein response. The over-production of ROS has
been evidenced to induce ER-stress which induces cellular
dysfunction and cell death.24 In the current study, we found
that a number of cellular proteins coming from MCF-7 and
MDA-MB-231 cells with their biological functions in protein
folding such as 78 kDa glucose-regulated protein and redox-
regulation such as peroxiredoxin-1 were significantly modu-
lated in protein expression during rhein treatment implying
that rhein might induce breast cancer apoptosis through
misfolding of cellular proteins as well as unbalancing of the
cellular redox status i.e. ER stress (Table S1, ESI†). In order to
prove this hypothesis, ER-stress has been determined and the
results indicated that rhein promotes ER-stress through the
upregulation of ER-stress markers, ERO1L, GRP78, PERK, IRE1-a
and calnexin. Importantly, compared with rhein-pretreated
MCF-7 and MDA-MB-231 cells, ER-stress was insignificant in
rhein-pretreated MCF-10A cells (Fig. 8).
3.6 Redox proteomic analysis of rhein-induced cysteine
modifications of MCF-7 and MDA-MB-231 proteins
Rhein has been reported to induce cytotoxicity via ROS genera-
tion in several diﬀerent cancer cell lines23 and we also confirm
ROS generation in MCF-7 and MDA-MB-231 cells (Fig. 2). We
thus hypothesized that rhein-induced ROS might damage or
deregulate cellular proteins by oxidative modification of their
cysteinyl thiol groups. Accordingly, we applied a recently devel-
oped redox 2D-DIGE methodology utilizing iodoacetylated ICy
dyes25 to assess rhein-induced changes in protein thiol reactivity.
Rhein-treated (15 mg mL1) or vehicle-treated cells were lysed
in the presence of ICy5 in triplicate. Individual ICy5-labeled
samples were then run on 2D gels against an equal load of
ICy3-labeled standard pool comprising of an equal mixture of
Fig. 5 Expression profiles for diﬀerentially expressed proteins potentially
contributing to: (A) protein folding, (B) cytoskeleton regulation and
(C) glycolysis. Horizontal bars represent fold-changes in protein expression
in rhein-treated versus untreated MCF-7 cells and MDA-MB-231 cells for each
protein. Additional details for each protein can be found in Table S1 (ESI†).
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both sample types to aid in spot matching and to improve the
accuracy of quantification. The ICy5-labeled samples were sub-
sequently labeled with the lysine labeling Cy2 dye as an internal
protein level control which was used to normalize the corres-
ponding ICy5/ICy3 signals. 1343 protein features were detected,
of which 242 displayed statistically significant diﬀerences in
labeling due to rhein treatment (Fig. 9). CCB post-staining and
matching with fluorescence images allowed confident picking of
129 gel features and 9 of these were identified as unique gene
products by MALDI-TOF peptide mass fingerprinting (Table S2,
ESI† and Fig. 9). All of the identified proteins contain at least one
cysteine, and since the ICy dyes target reduced cysteinyl thiols,
these results suggest that rhein alters the oxidative status
of some of these thiol groups. The possible biological roles of
these modifications are discussed below and warrant further
investigation. The diﬀerentially labeled proteins were mostly
Fig. 6 Validation of rhein-induced diﬀerential protein expression in MCF-7 cells by immunoblotting and enzyme-linked immunosorbent
assay. The altered expression of identified proteins; (A) cathepsin D, (B) galectin-3 and (C) HSP-27 were assessed by immunoblotting (left
panels), while ELISA analysis was performed to determine the levels of (D) tropomyosin alpha-4 and (E) destrin in rhein-treated versus
untreated MCF-7 cells (left panels). The protein 2D-DIGE map (right top panels) and three-dimensional spot image (right bottom panels) are
also shown.
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cytoplasmic and fell into several functional groups including
cytoskeleton regulation, protein translation, immuno response,
protein folding, redox regulation and glycolysis (Table S2, ESI†).
3.7 Validation of redox-induced changes in peroxiredoxin-2
To validate alterations of thiol reactivity of the identified pro-
teins, immunoprecipitation combined with immunoblotting
was performed to compare the free thiol group levels and protein
expression levels between rhein- and control-treated MCF-7 cells.
In here, we choose one of the most significant change proteins,
peroxiredoxin-2, to validate the thiol reactive alterations on
this protein. Validation result confirmed the increase of free
thiol content of peroxiredoxin-2 and no significant change of the
protein level in rhein-treated MCF-7 cells compared to untreated
cells (Fig. 10).
4. Discussion
Extensive attention has been paid to the identification of naturally
occurring chemotherapeutic botanicals which are able to inhibit,
delay or reverse tumorigenesis or metastasis. The assessment of
ancient herbal medicines might oﬀer an approach for the treat-
ment of breast cancer, which remains a primary cause of cancer-
related deaths all over the world.26 In the present study, we
examined the molecular mechanisms of rhein cytotoxicity in
breast cancer cells in vitro since rhein has been shown to exhibit
Fig. 7 Validation of rhein-induced diﬀerential protein expression in MDA-MB-231 cells by immunoblotting, immunofluorescence and ELISA. The altered
expression of identified proteins; (A) 78 kDa glucose-regulated protein, (B) annexin A3, (C) SCaMC-3, (D) cofilin-1, (E) galectin-1, (F) cytoskeletal 18,
(G) nucleobindin-1, (H) peptidyl-prolyl cis–trans isomerase A, (I) peroxiredoxin-1, (J) protein disulfide-isomerase A3, (K) stress-induced-phosphoprotein
1 and (L) tropomyosin alpha-1 were assessed by immunoblotting (left panels), while immunofluorescence analysis and ELISA analysis were performed to
determine the levels of (M) cytoskeletal 19 and (N) 60 kDa heat shock protein in rhein-treated versus untreated MDA-MB-231 cells (left panels),
respectively. The protein 2D-DIGE map (right top panels) and three-dimensional spot image (right bottom panels) are also shown.
Paper Molecular BioSystems
Pu
bl
ish
ed
 o
n 
22
 S
ep
te
m
be
r 2
01
4.
 D
ow
nl
oa
de
d 
by
 N
at
io
na
l C
hu
ng
 H
sin
g 
U
ni
ve
rs
ity
 o
n 
12
/0
2/
20
15
 1
0:
16
:4
6.
 
View Article Online
3096 | Mol. BioSyst., 2014, 10, 3086--3100 This journal is©The Royal Society of Chemistry 2014
anti-tumorigenic ability in several diﬀerent cancer types.27,28 By
means of 2D-DIGE and MALDI-TOF MS, more than 70 rhein-
induced alterations in protein expression have been identified in
either MCF-7 or MDA-MB-231 cells. The results demonstrate that
this strategy is powerful enough to identify a broad-ranging
signature of rhein-induced cytotoxicity, with the altered proteins
having roles in cytoskeleton regulation, protein folding, cytoskeleton,
glycolysis, signal transduction and transcription control. Even
though the global coverage of protein mixtures identified by
LC-MS based analysis is generally recognized to be higher than
that of 2-DE based analysis, 2-DE based analysis oﬀers the
advantage of direct protein quantification at the protein isoform
level with reduced analytical variation.9 Our study also revealed
that treatment of breast cancer cells with rhein results in the
generation of reactive oxygen species. Since ROS can activate
signaling pathways, modulate a variety of cellular activities and
regulate disease progression, it is important to study the molecular
events associated with their eﬀects. Accordingly, our previously
established cysteine-labeling 2D-DIGE platform using ICy3/ICy5
dyes was thus used to determine if protein thiol reactivity is altered
in cells following treatment with rhein due to ROS generation.
Our previous studies using MCF-7 cells as an in vitro model
revealed that treatment with rhein results in decreased cell
viability at least partially through the over-expression of p21,
caspase-9 and ASK1 expression.22 In addition, current proteomic
analysis revealed that heterogeneous nuclear ribonucleoprotein
K and heterogeneous nuclear ribonucleoproteins A2/B1, key
eukaryotic mRNA processing proteins, were down-regulated in
response to rhein treatment. Previous report demonstrated that
down-regulated of heterogeneous nuclear ribonucleoprotein K
mediating TRAIL-induced apoptosis and reducing FLIP-involved
anti-apoptotic activity.29 Additionally, down-regulation of hetero-
geneous nuclear ribonucleoproteins A2/B1 leads to the increased
formation of pro-apoptotic Bcl-x(s) and promoted apoptosis of
BxPc3 cells.30 Thus, the down-regulation of heterogeneous nuclear
ribonucleoprotein K and heterogeneous nuclear ribonucleo-
proteins A2/B1 may contribute to rhein-induced apoptosis of
breast cancer cells through inactivation of mRNA processing.
Another identified rhein-induced down-regulated protein was
galectin-3, which has been reported to promote cancer cell
proliferation and suppress cancer cell apoptosis.31,32 Galectin-3
was previously shown to modulate CD95, a member of the tumor
necrosis factor family, and inhibit the apoptotic signaling
pathway.33 Overexpression of galectin-3 has been evidenced to
prevent bladder carcinoma cells from TRAIL-induced apoptosis
through constitutive activation of Akt, whereas blockage of the
Fig. 8 Rhein-induced increase in ER-stress in MCF-7 cells and MDA-MB-231 cells. (A) The levels of ER-stress proteins, ERO1L, GRP78, PERK, IRE1-a and
calnexin were confirmed by immunoblot analysis. (B) The statistical analysis of rhein-induced alterations against untreatment of these ER-stress proteins
was displayed.
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PI3K signaling pathway significantly reduced the protecting
eﬀect of galectin-3 on cell apoptosis suggesting that galectin-3
involves Akt as a modulator molecule in protecting bladder
carcinoma cells from TRAIL-induced apoptosis.34 Accordingly,
the down-regulation of galectin-3 may contribute to rhein-
induced apoptosis of breast cancer cells through inactivation
of Akt and subsequent activation of TRAIL-related apoptosis.
Our proteomic analysis revealed rhein to down-regulate the
majority of identified proteins which are involved in a variety
of cellular processes including protein folding, cytoskeleton
regulation and glycolysis (Fig. 5). We hypothesize that rhein
may interfere with the proper folding of cellular proteins through
the reduced expression of folding and protein chaperones such as
60 kDa heat shock protein, 78 kDa glucose-regulated protein, heat
shock cognate 71 kDa protein, heat shock protein beta-1, peptidyl-
prolyl cis–trans isomerase A, protein disulfide-isomerase A3 and
mitochondrial stress-70 protein and that this may be linked to a
general stress response as well as ER stress response. Importantly,
peptidyl-prolyl cis–trans isomerase A has been reported to be able
to inactivate procaspase-3 activity through sequestering cyto-
chrome c.35 Accordingly, it is tempting to consider that rhein
might trigger apoptosis of MCF-7 and MDA-MB-231 cells at least
partially through the down-regulation of peptidyl-prolyl cis–trans
isomerase A. Mitochondria are well-defined to play a major role in
regulating cellular apoptosis36 and recent reports indicate that
rhein inhibits mitochondrial electron transport37 and induces
apoptosis through a mitochondria/caspase-dependent pathway
in human kidney cells.38 The deregulation of mitochondrial
Fig. 9 Redox 2D-DIGE analysis of rhein-induced diﬀerential cysteine-modification in MCF-7 cells and MDA-MB-231 cells. (A) Lysates from MCF-7 cells
and MDA-MB-231 cells treated with 15 mg mL1 of rhein or left untreated were subjected to redox 2D-DIGE analysis as described in Materials and
methods. Images of protein samples from untreated and rhein-treated MCF-7 cells and MDA-MB-231 cells are displayed. (B) Identified diﬀerentially
labeled protein features are annotated with spot numbers.
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electron transport proteins in the current study appears to
support this.
Particularly, all of the identified proteins with roles in
cellular metabolism (mainly glycolytic enzymes) were found
to be down-regulated, implying relationship between rhein-
induced apoptosis and cellular metabolism in breast cancer.
In fact, it has been previously revealed that BAD, a member of
pro-apoptotic Bcl-2 family, exists in a glucokinase-containing
complex in the mitochondrion that modulates glucose-
dependent mitochondrial respiration and cell death dependent
upon glucose availability.39,40 Consequently, rhein might dereg-
ulate glycolysis in both MCF-7 and MDA-MB-231 cells via its
eﬀect on pro-apoptotic proteins such as BAD. Notably, the
identified glycolytic enzymes including triosephosphate iso-
merase, fructose-bisphosphate aldolase A and alpha-enolase
displayed significant down-regulation, also supporting previous
data demonstrating that oxidative stress can redirect carbo-
hydrate fluxes to generate increased reducing power in the form
of NADPH at the expense of glycolysis.41,42
Rhein has been reported to induce ROS which are essential
mediators of attenuated tumor growth and cancer cell apoptosis.8
These processes are mediated by increasing endoplasmic reti-
culum stress, blocking the G2/M checkpoint, reducing mito-
chondrial potential, promoting the expression of caspases and
activation of JNK and p38 MAPK signaling pathways. Our present
data support these observations that rhein can induce cell death
in MCF-7 and MDA-MB-231 cells through the generation of ROS
and the G2/M transition.
ROS are known to modify protein cysteinyl thiol groups,
resulting in oxidative damage.43–45 We therefore applied a
recently developed 2D-DIGE methodology utilizing iodoacetyl
ICy dyes to assess rhein-induced changes in the thiol reactivity
of cellular proteins in MCF-7 cells and MDA-MB-231 cells.
Individual ICy5- and Cy2-labeled samples were run on 2D gels
against an equal load of an ICy3-labeled standard pool consisting
of an equal mixture of the differentially treated samples to
accurately determine changes in the thiol reactivity of the
proteins. This experimental design accurately quantified
changes in the thiol reactivity of cysteine residues taking into
consideration variation due to protein expression change.
The ICy labeling data presented support the hypothesis
that rhein can induce the formation of free thiols in certain
proteins through disruption of disulphide bonds; meanwhile,
rhein induced ROS or protein-derived peroxides may directly
oxidize thiol groups to form the sulfenic, sulfinic or sulfonic
acid forms of cysteine, which would not react with the ICy dyes.
These thiol modifications have been reported to perturb
the normal functions of the proteins.46 In the current study, 9
proteins with diﬀerential thiol reactivity were identified by
MALDI-TOF MS. Peroxiredoxin-2, galectin-3, triosephosphate
isomerase, peptidyl-prolyl cis–trans isomerase A and cofilin-1
are reported tomaintain the cell redox status and protein folding
as well as regulate glycolysis and cytoskeleton formation and
all displayed an increase in ICy dye labeling following rhein
treatment (Table S2, ESI†). Thus, their cysteine residues must be
reduced to generate new thiol groups for ICy labeling, implying
possible oxidative damage and deregulation of these proteins.
In contrast, several of the identified proteins, such as elongation
factor 1-delta, phosphoglycerate mutase 1, heat shock protein
beta-1 and peroxiredoxin-1, displayed a decrease in ICy dye
labeling following rhein treatment (Table S2, ESI†). Thus, their
free thiol groups must be oxidized in response to rhein treatment
to block ICy labeling, implying possible oxidative damage and
deregulation of these proteins.
In conclusion, the present study oﬀers an insight into
the mechanisms of rhein-induced apoptosis in human breast
cancer cells and shows a link between ROS generation and the
cell death process. Further study also indicated that rhein
promotes misfolding of cellular proteins as well as unbalancing
of cellular redox status leading to ER-stress. The findings of this
study may have clinical implications in that rhein treatment
may be useful in destroying fast-growing cancer cells with
limited toxicity to normal cells. Additionally, numerous identified
cellular proteins may be useful for further evaluation as potential
targets in breast cancer therapy.
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2-DE Two-dimensional gel electrophoresis
CCB Colloidal coomassie blue
CHAPS 3-[(3-Cholamidopropyl)-dimethylammonio]-
1-propanesulfonate
DCFH-DA 2,7-Dichlorofluorescin diacetate
ddH2O Double deionized water
DIGE Diﬀerential gel electrophoresis
DTT Dithiothreitol
EDTA Ethylenediaminetetraacetic acid
FCS Fetal calf serum
MALDI-TOF MS Matrix assisted laser desorption ionization-
time of flight mass spectrometry
NP-40 Nonidet P-40
Fig. 10 Validation of the thiol reactive protein, peroxiredoxin-2, identified
through a redox-proteomic study in MCF-7 cells after rhein treatment by
IP-WB. ICy dye-labeled protein samples from MCF-7 cells were either
untreated or treated with 15 mg mL1 of rhein followed by immunopreci-
pitation with anti-peroxiredoxin-2 antibody to confirm the alterations of
thiol reactivity in peroxiredoxin-2. The image was visualized by Ettan DIGE
imager. Immunoblotting against the corresponding antibody was performed
to gain the protein level.
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